Gene Editing Shop Recombinetics Surpasses $2M Fundraising Goal | GenomeWeb

NEW YORK (GenomeWeb News) – Gene editing firm Recombinetics today said that it surpassed its $2 million fundraising goal this month.

The St. Paul, Minn.-based firm did not disclose its investors.

Founded in 2008, Recombinetics is using a gene editing technology called TALENs to produce its first biomedical product and to develop the first agricultural products, it said on its website.

TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.